ALNYLAM PHARMACEUTICALS, INC. ($ALNY)
Filing Information
| Accession Number | 0001735276-26-000063 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 6, 2026 |
| Document | View SEC Filing |
Transactions
12
Total Shares
4,713
Total Value
$1,524,795.55
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP Chief R&D | Common Stock | โ | Mar 4, 2026 | Sale | 106 | $319.03 | $33,817.18 | 23,300 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 4, 2026 | Sale | 102 | $320.01 | $32,641.02 | 23,198 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 4, 2026 | Sale | 215 | $320.81 | $68,974.15 | 22,983 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 4, 2026 | Sale | 289 | $321.82 | $93,005.98 | 22,694 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 4, 2026 | Sale | 350 | $323.01 | $113,053.50 | 22,344 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 4, 2026 | Sale | 767 | $323.84 | $248,385.28 | 21,577 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 4, 2026 | Sale | 272 | $324.88 | $88,367.36 | 21,305 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 4, 2026 | Sale | 208 | $325.67 | $67,739.36 | 21,097 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 5, 2026 | Sale | 654 | $322.33 | $210,803.82 | 20,443 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 5, 2026 | Sale | 740 | $323.55 | $239,427.00 | 19,703 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 5, 2026 | Sale | 510 | $324.59 | $165,540.90 | 19,193 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 5, 2026 | Sale | 500 | $326.08 | $163,040.00 | 18,693 | Direct | โ | View Details |